Personalizing antibiotic treatment for pneumonia in patients on ventilators
Personalizing Antimicrobial Use in Ventilator-Associated Pneumonia
This study is looking to make the treatment of ventilator-associated pneumonia better by finding ways to personalize how long patients need antibiotics, so they get the right care without extra side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11118911 on NIH RePORTER |
What this research studies
This research focuses on improving the treatment of ventilator-associated pneumonia (VAP), a serious infection that affects patients on mechanical ventilation. The current standard treatment involves administering antibiotics for a fixed duration, which may not be suitable for all patients. The project aims to identify specific biomarkers in the lungs that can help tailor antibiotic treatment durations to individual patient needs. By validating new analytical methods, the research seeks to enhance the effectiveness of antibiotic therapy and reduce unnecessary side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are hospitalized patients who are on mechanical ventilation and diagnosed with ventilator-associated pneumonia.
Not a fit: Patients who are not on mechanical ventilation or do not have ventilator-associated pneumonia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective antibiotic treatments for patients with ventilator-associated pneumonia, potentially improving recovery rates and reducing complications.
How similar studies have performed: Previous research has shown promise in personalizing antibiotic treatments based on biomarkers, indicating that this approach could lead to significant advancements in patient care.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Albin, Owen — University of Michigan at Ann Arbor
- Study coordinator: Albin, Owen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.